The World Health Organization has prequalified the first antimalarial drug specifically for newborns and infants weighing 2–5 kg, a significant advancement in combating malaria in the most vulnerable population.

• This new artemether-lumefantrine formulation is the first antimalarial safe for babies under 5 kg, previously treated with drugs carrying risks of dosing errors and toxicity.
• Key organization involved: World Health Organization (WHO).
• The approval, announced on April 24, 2026, allows countries to authorize the drug and enables UN agencies to procure and distribute it in malaria-endemic areas.